Josh Meyer

@ASTRO_org @FoxChaseCancer Incredibly humbled to be granted this honor by ASTRO and to part of such a wonderful class of fellows being inducted. Privileged to be a part of such a wonderful organization!

2025 ASTRO Fellow Spotlight Series Congratulations Joshua Meyer, MD from Fox Chase Cancer Center We look forward to recognizing you at #ASTRO25 ow.ly/JEkT50WAn9K @FoxChaseCancer

Thanks to ESTRO for providing important context to the PROSPECT study.

This type of marketing of protons doesn't instill confidence in our field IMO. The site is aptly titled askforprotons.com On it, there is a quiz w 4 questions (age, prior RT, tumor site), but no matter what answers you put, it tells you protons may be needed.

The American Society for Radiation Oncology (ASTRO) Gastrointestinal Cancers Resource Panel issued the following statement regarding the PROSPECT clinical trial for patients with rectal cancer: astro.org/News-and-Publi…

@PrajnanDasMD Very well said!

If TNT > preop chemoRT (PRODIGE, RAPIDO) and preop chemo = preop chemoRT (PROSPECT) it seems to logically follow that TNT > preop chemo. For most patients today, the standard of care is TNT which includes RT

Congrats to the authors of the PROSPECT trial! A tremendous accomplishment. #ASCO23 Some thoughts:

@subatomicdoc @SprakerMDPhD @GI_RadOnc @Medscape @NiuSanford • How does this impact non-operative management? • How do we treat pts with suspicious lateral LNs or other LNs not defined as perirectal in the protocol? • While removing CRT was done in the name of QoL, do the data really support that? Will be excited to see full QoL data!

@subatomicdoc @SprakerMDPhD @GI_RadOnc @Medscape @NiuSanford Very impressed with the authors who conducted a difficult study in a shifting landscape that maintained relevance when it finally came out. Results took so long bc pts did so well on both arms. As the best studies do, this one leaves me with more questions than answers:

Ok, this exactly was my concern after the presentation of the PROSPECT trial at #ASCO23. It’s not „many patients with locally advanced rectal cancer“ it’s “Many patients who met the inclusion criteria of the PROSPECT study”. Longer thread to follow… @Medscape

@kharofaJ Very excited to see these results that have been a long time coming. I predict it will make rectal ca even MORE confusing to treat, with lots of room for additional work on patient selection

@MikeChuongMD @MiamiCancerInst @viewray @NiuSanford @TedHong9 @whallradonc @RadDocMReyngold @JoeHermanMD I’ve only used this once and had great results, but unfortunately they didn’t last. I didn’t target the whole pancreatic mass, just the plexus, and think the mass probably grew back and put new pressure on the plexus. I’ll do it differently next time!

@MiamiCancerInst @viewray Although 25 Gy prescribed, delivered dose was higher Mean/max GTV: 32.4 Gy/35.1 Gy Mean/max PTV: 31.1 Gy/35.1 Gy Unanswered questions: -optimal dose? -should gross dz be targeted or just celiac plexus region? @NiuSanford @TedHong9 @whallradonc @RadDocMReyngold @JoeHermanMD

Radiosurgery (25 Gy/1 fx) for tumor around celiac axis causing debilitating pain refractory to meds. 3 days later pain nearly gone, no side effects. "You gave me my life back!!" the patient told me this morning almost in tears. Today was a great day. @MiamiCancerInst @viewray

@MikeChuongMD @MiamiCancerInst @viewray Excellent! LC and QoL! like killing two birds with one stone!

@ldawsonmd @LeilaTchelebi @kharofaJ @Dan_ChangMD @nbn426 @KrishanJethwa @NiuSanford @adapthyun @AnkerUVMRadOnc @SalmaJabbour1 @MikeChuongMD @lauren_henke @JoeHermanMD @KarynAGoodman @TedHong9 @jryckman3 @whallradonc @PrajnanDasMD @freddyeescorcia @RadDocMReyngold @themednet @NRGonc Great discussion! For our mets pts, we don’t worry about biliary tree and treat with 5 fxs. For HCC or cholangio pts we contour the CHBT and if we can’t stay under and get 50 Gy, drop to 15 fractions (with no biliary constraints).

@LeilaTchelebi @kharofaJ @Dan_ChangMD @nbn426 @KrishanJethwa @NiuSanford @adapthyun @AnkerUVMRadOnc @SalmaJabbour1 @MikeChuongMD @lauren_henke @JoeHermanMD @KarynAGoodman @TedHong9 @jryckman3 @whallradonc @PrajnanDasMD @freddyeescorcia @RadDocMReyngold @themednet @NRGonc We use 5 # SBRT routinely for HCC or mets, up to 50 Gy, avoiding hotspots on actual biliary tree (contoured). 15 fraction regimen preferred for cholangio. I strongly recommend avoiding 3 or 1 # SBRT in central biliary ‘no fly zone’ ( not contoured) - 1.5cm around biliary tree

#GIonc #Radonc friends- question for you! Would enjoy learning your approach Pt with centrally located liver tumor approaching central biliary tree (primary or oligomet), multi-D recommendation= RT What’s your approach for central biliary tree?

@lauren_henke @MikeChuongMD @NiuSanford I have had great luck with this too!

@MikeChuongMD @NiuSanford I’d be game!

Doctors at a major US insurance company deny tens of thousands of claims a month without even looking at patients’ files. “We literally click & submit,” a former Cigna doctor told @ProPublica & @Capitol_Forum. “It takes all of 10 seconds to do 50 at a time.” The inside story 🧵

Boom!

ChatGPT tech could revolutionize healthcare!!! BUT what are its current shortcomings and potential DANGERS??? 🧵

We’re hiring for an outstanding opportunity as PI of a lab with appointments in Rad Onc and the Institute for Cancer Research at Fox Chase. Exciting collaborative atmosphere with resources and support. Please share and contact me with questions. careers.cell.com/job/10028/asst…

Temple University is tapping North Philly community members to help choose its medical students. What a great idea and fantastic use of the wonderful resource that is the Temple community! inquirer.com/news/temple-un…

Researchers at Fox Chase have shown in a recent study that taking a new approach to targeting a well-established cancer-promoting pathway may be effective in stopping the progression of certain cancers. Read more about this study: bit.ly/3Op6buz

Pancreatic cancer remains one of the most challenging cancers to fight. But improvements in a long-standing procedure are helping doctors chip away at it. Hear from Dr. @SanjaySReddy on how FCCC is treating pancreatic cancer in new ways: 6abc.cm/3QRS9mS @6abcaction

🚨@Oncoalert: #RadOnc is "constantly working to improve survival & patient well-being, form deep connections with our pts, & push the boundaries of medical innovations." Proud of this @Medscape column w/ Dr @fantinegiap discussing what makes #radonc unique medscape.com/viewarticle/97…